Oncology PCR Markers Market: By PCR Markers Type (Taqman Probe, SYBR Green, RAPD, ISSR, EST-SSR, Microsatellite, CAPS), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cancer, Others), By End-User (Hospitals, Cancer Care Centers, Diagnostic Labs, Others), and Geography

Oncology PCR Markers Market size was valued at USD 13,683.2 million in 2023 and is expected to grow at an 8.1% CAGR from 2024 to 2030. Oncology PCR markers play a crucial role in this by detecting minute quantities of RNA molecules indicative of cancerous cells. Tumor-specific biomarkers, such as oncogenes, tumor suppressor genes, and fusion genes, serve as targets for RT-PCR analysis. A molecular oncology PCR marker is used to identify the size of the detected PCR product from a suspected oncology sample. The growth of the oncology PCR market can be largely attributed to the factors, such as the rising prevalence of cancer, worldwide, technological advancements in diagnostic testing, and increasing demand for point-of-care testing. The rising prevalence of cancer cases across the world is contributing to the increasing demand for diagnosis, which is boosting the oncology PCR markers market. Moreover, behavioral and dietary changes such as low physical activity, high tobacco and alcohol uptake, low intake of healthy food, and obesity account for the increase in cancer cases globally.

According to the World Health Organization (WHO), cancer accounted for approximately 10 million deaths in 2020. Additionally, due to the increasing technological advancements in diagnostic testing, there is a growing usage of molecular diagnostic tests like PCR for oncology. Several advancements are being made in cancer genome sequencing, computational analysis, tumor models, and innovative cancer research methods. For instance, Roche Molecular Systems, Inc. developed the Cobas EGFR Mutation Test for non-small cell lung cancer patients and received approval from the USFDA in 2020 and is a real-time PCR test to detect 42 mutations of the epidermal growth factor receptor (EGFR) gene. Moreover, molecular tests using PCR are being used more frequently due to improvements in diagnostic testing technologies. The expansion in the field of molecular biotechnology, rising demand for synthetic biology, and increasing investment in R&D by key players are the main factors fueling the rapid growth of the oncology PCR markets market.

However, the high cost of oncology PCR markers tests, lack of skilled workforce, and stringent regulatory framework are some of the factors impeding the market growth. The use of oncology PCR markers tools for oncology is predicted to rise due to increased patient and healthcare professional awareness of the importance of early cancer detection and distinction. Moreover, the PCR technology holds the potential for the highest revenue share. This can be attributed to its growing utilization in research labs and the increased need for enhanced diagnostics.

Oncology PCR Markers Market Key Developments:

• In April 2024, Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ESR1Mutation Detection Kit for Breast cancer.